Igene Biotechnology, Inc.
IGNE · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Market Cap | $15,654 | $7,827 | $17,190 | $15,503 |
| - Cash | $269 | $977 | $1,276 | $1,295 |
| + Debt | $7,336 | $7,329 | $7,197 | $6,796 |
| Enterprise Value | $22,720 | $14,178 | $23,111 | $21,004 |
| Revenue | $0 | $0 | $0 | $5 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $41 |
| % Margin | – | – | – | 850.3% |
| EBITDA | -$58 | -$89 | -$110 | -$201 |
| % Margin | – | – | – | -4,187.1% |
| Net Income | -$627 | -$811 | -$549 | -$386 |
| % Margin | – | – | – | -8,043% |
| EPS Diluted | -0 | -0.001 | -0 | -0 |
| % Growth | 20% | -25% | -100% | – |
| Operating Cash Flow | -$711 | -$290 | -$13 | -$669 |
| Capital Expenditures | $0 | -$7 | $0 | $24 |
| Free Cash Flow | -$711 | -$297 | -$13 | -$645 |